Default company panoramic image
F68ea097 93ba 4b89 8675 a7ffcd0a3f81

AesRx, LLC

AesRx is developing two orphan drugs. Aes-103 for sickle cell disease is a potential blockbuster. Aes-210 for pouchitis is in Phase 2

  • Stage Not Set
  • Industry Biotechnology
  • Location Newton, MA, USA
  • Currency USD
  • Employees 3
  • Website aesrx.com

Company Summary

Aes-103 is a novel, orally bioavailable small molecule drug for sickle cell disease (SCD). AesRx is developing Aes-103 in collaboration with the NIH. A Phase 1 trial is complete and a Phase 1/2a trial in SCD patients is expected to begin at the NIH in 2Q12. There are 75,000-100,000 SCD patients in the US and 40,000 in the EU. The FDA has designated Aes-103 as an Orphan Drug. JP Morgan estimates the market for a SCD drug to be $4+ billion.

Team

  • Default avatar
    Stephen Seiler
    Chief Executive Officer

  • Default avatar
    Warren Stern
    SVP - Drug Development

  • Default avatar
    Maggie LeFlore
    Director

  • Default avatar
    Mary Pendergast
    Director

  • Default avatar
    Colin Hill
    Director

Advisors

  • Default avatar
    Joe Faber, Faber Daeufer & Rosenburg
    Lawyer
    Unconfirmed
    Default avatar
    Bloom Cohen Hayes
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    self-funded
    Unconfirmed